Paving the Way for Therapy: The Second International Conference of the Trisomy 21 Research Society
暂无分享,去创建一个
P. D. De Deyn | C. Lemere | M. Dierssen | J. Delabar | E. Head | M. Potier | J. Busciglio | A. Bhattacharyya | P. Caviedes | A. Dekker | R. Reeves | P. D. de Deyn
[1] R. Malenka,et al. Hippocampal Long-Term Potentiation Suppressed by Increased Inhibition in the Ts65Dn Mouse, a Genetic Model of Down Syndrome , 2004, The Journal of Neuroscience.
[2] D. Gozal,et al. Urinary biomarkers and obstructive sleep apnea in patients with Down syndrome. , 2017, Sleep medicine.
[3] D. Linden,et al. Hedgehog Agonist Therapy Corrects Structural and Cognitive Deficits in a Down Syndrome Mouse Model , 2013, Science Translational Medicine.
[4] Fabian Fernandez,et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome , 2007, Nature Neuroscience.
[5] M. Dierssen,et al. Changing Paradigms in Down Syndrome: The First International Conference of the Trisomy 21 Research Society , 2016, Molecular Syndromology.
[6] Philip D. Gregory,et al. Translating Dosage Compensation to Trisomy 21 , 2013, Nature.